Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis

INTRODUCTION: It is currently unclear which cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, combined with endocrine therapy, is the preferred treatment approach in patients with hormone receptor (HR)-positive, human epidermal receptor-2 (HER2) negative metastatic breast cancer. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Qiancheng, Kang, Wenli, Wang, Qingfeng, Luo, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152932/
https://www.ncbi.nlm.nih.gov/pubmed/35636793
http://dx.doi.org/10.1136/bmjopen-2021-056374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152932/
https://www.ncbi.nlm.nih.gov/pubmed/35636793
http://dx.doi.org/10.1136/bmjopen-2021-056374

Ejemplares similares